Liquid-filled capsules (LFC) are the primary delivery platform for oral delivery of lipid formulations which includes both soft elastic capsules and liquid filled hard capsules. Liquid-in-bottle is another avenue for delivering lipid formulations. Proper deployment of these technologies can provide formulators with effective delivery platforms during early-phase development and commercial products.
Join industry experts for a discussion on strategies to develop lipid-based drug delivery systems (LBDDS) for oral delivery. The experts will present the fundamental principles, advantages and disadvantages of different dose forms for LBDDS and share considerations for selecting a suitable dose form for early phase development programs through commercialization.
David Fulper, Ph.D., Director, Technology Support, Catalent Pharma Solutions
David Fulper has been working with soft gelatin capsules and liquid filled hard shell capsules for the last 15 years. Prior to Catalent, he was director for liquid filled capsules at Patheon in Cincinnati, OH. He received his Ph.D. in Pharmaceutics from the University of Mississippi, Oxford, MS.Message Presenter
Kishor M. Wasan, R.Ph., Ph.D., Fellow, AAPS Professor, College of Pharmacy and Nutrition, University of Saskatchewan
Dr. Kishor M. Wasan is a professor and former Dean at the College of Pharmacy and Nutrition at the University of Saskatchewan. He has published over 200 peer-reviewed articles and 240 abstracts in the area of lipid based drug delivery and lipoprotein-drug interactions. Dr. Wasan completed his undergraduate degree in pharmacy at the University of Texas at Austin and his Ph.D. at the University of Texas Medical Center in Houston Texas at MD Anderson Cancer Center in Cellular and Molecular Pharmacology.Message Presenter
Who Should Attend?
Scientists in the industry with a baseline knowledge of LBDDS who are considering using LBDDS for their drug product.
- Formulation Developer
- Pharmaceutical Formulation Scientist
- Program Managers, Drug Development
- Formulation R&D
What You Will Learn
Key learning objectives include:
- How and why LBDDS can support your bioavailability strategy
- The variety and different properties of LBDDS dosage forms
- How to navigate the dosage form development path from clinical phase to commercialization
Catalent is the leading global provider of advanced delivery technologies and development and manufacturing solutions for drugs, biologics, gene therapies and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply.